ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
Panelists discuss how distinguishing between limited-stage and extensive-stage small cell lung cancer is essential for guiding treatment strategies, accurately staging disease, and setting appropriate expectations for prognosis and therapeutic outcomes.
Summary for Physicians:
The distinction between extensive-stage small cell lung cancer (ES-SCLC) and limited-stage SCLC (LS-SCLC) is critical in understanding differences in disease burden and prognosis.
- ES-SCLC involves disease that has spread beyond a single hemithorax and is not suitable for inclusion within a single, tolerable radiation field. It often includes distant metastases, such as to the liver, brain, or bones. This stage is associated with a higher tumor burden and a poorer prognosis, with median overall survival typically around 8–13 months, even with systemic therapy.
- LS-SCLC is confined to one hemithorax and regional lymph nodes and can be encompassed within a single radiation field. It generally presents with a lower tumor burden and has a relatively better prognosis, with median survival ranging from 15–20 months. A subset of patients may achieve long-term survival with curative-intent chemoradiation.
Understanding this distinction is essential for accurate staging, therapeutic decision-making, and setting realistic expectations for outcomes.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
